Abstract: The receptor activator of NF-B (RANK) ligand (RANKL) is a cytokine that is essential for osteoclast development, whereas interleukin (IL)-18 suppresses osteoclastogenesis by increasing granulocyte-macrophage colony-stimulating factor (GM-CSF) production in T-cells. In the present study, we examined the effect of RANKL on the expression of IL-18 and IL-18 binding protein (IL-18BP), a natural inhibitor of IL-18, in RAW264.7 cells. We also examined the effect of conditioned medium derived from RAW264.7 cells on IL-18-induced GM-CSF expression in CD4 + T cells isolated from the spleens of C57BL/6J mice. mRNA expression of IL-18 was significantly suppressed, whereas that of IL-18BP was significantly increased in RANKL-treated RAW264.7 cells compared with untreated cells. RANKL also increased the expression of IL-18BP protein in culture supernatants of RAW264.7 cells. GM-CSF protein expression in CD4 + T-cells stimulated with IL-18 was suppressed by the addition of conditioned medium derived from RANKL-treated RAW264.7 cells. These results suggest that RANKL suppresses the stimulatory effect of IL-18 on GM-CSF expression in CD4 + T-cells via enhancing the production of IL-18BP in RAW264.7 cells.
Introduction
Osteoclast differentiation is controlled by cellular signals and cytokines 1) . Inflammation-mediated bone loss is a major feature of various bone diseases, including chronic periodontitis, rheumatoid arthritis and osteoarthritis; in these diseases, inflammatory tissue is a major source of a broad range of cytokines that are involved in osteoclast differentiation and activation 2) . The receptor activator of NF-B (RANK) ligand (RANKL) is a cytokine that is essential for osteoclast development 1, 3) .
Osteoclastogenesis is strongly induced when membrane-anchored or soluble RANKL binds to RANK on osteoclast precursor cells 1, 3, 4) . In addition, pro-inflammatory cytokines, including tumor necrosis factor-, interleukin (IL)-1, IL-6, and IL-17, induce the differentiation of mature osteoclasts from osteoclast precursor cells via promoting RANKL expression in synovial fibroblasts, T lymphocytes and osteoblasts 2, 5, 6) . However, IL-6 and IL-17 also play a role analogous to anti-osteoclastogenic factor when proinflammatory cytokines directly act on osteoclast precursor cells.
IL-6 inhibits osteoclast differentiation by suppressing RANK signaling in osteoclast progenitors 7) . We previously reported that the effect of IL-17 conflicts with the direct action on osteoclast precursors and indirect action through osteoblasts [8] [9] [10] . Thus, the differentiation of osteoclast precursors into osteoclasts is suppressed at high concentrations of IL-17 in the presence of RANKL 8, 9) . On the other hand, IL-17 induces the differentiation of osteoclast precursors into osteoclasts by increasing RANKL expression and decreasing that of osteoprotegerin, a physiological inhibitor of RANKL, in osteoblasts 8, 10) . IL-18 is also known to inhibit and promote osteoclastogenesis. In an in vitro co-culture system using osteoblasts and spleen cells, IL-18 suppresses osteoclast formation by enabling T-cells to promote the expression of granulocyte-macrophage colonystimulating factor (GM-CSF), a differentiation factor for dendritic cells rather than osteoclasts [11] [12] [13] . However, several reports have indicated that IL-18 plays a destructive role in rheumatoid arthritis 14) . IL-18 stimulates osteoclast formation via upregulation of RANKL production in T-cells derived from synovitis in rheumatoid arthritis 15, 16) .
IL-18 binding protein (IL-18BP) functions as a decoy receptor that prevents the interaction between IL-18 and the IL-18 receptor; 18BP 17, 18) . The imbalance of IL-18 to IL-18BP can be associated with the onset of diseases such as sepsis, Crohn's disease or rheumatoid arthritis 18) . Previous studies have reported that monocytes 19) and macrophages 20) produce IL-18BP; however, the role of IL-18BP in the cellular interaction between osteoclast precursor cells and T-cells via IL-18 during the process of osteoclast differentiation is less-understood. Therefore, we conducted this study using the murine monocyte/macrophage cell line RAW264.7 as osteoclast precursors and CD4 + T cells derived from the mouse spleen to examine the effect of RANKL on IL-18BP and IL-18 expression in RAW264.7 cells. We also examined the effect of conditioned medium derived from RANKL-treated RAW264.7 cells on IL-18-induced GM-CSF expression in CD4 + T cells.
Materials and Methods

Osteoclast cultures and tartrate-resistant acid phosphatase (TRAP) staining
The murine monocyte/macrophage cell line RAW264.7 21) was purchased from Dainippon Pharmaceutical (Osaka, Japan). Cells were seeded onto 96-well or 6-well flat-bottomed culture plates at a density of 5 × 10 3 cells/cm 2 . After overnight incubation, cells were cultured for up to 5 days in -Minimal Essential Medium ( -MEM) containing 10% fetal bovine serum (FBS; HyClone Laboratories, Logan, UT, USA), 1 % (v/v) penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, USA), and 0 or 50 ng/ml soluble RANKL (Wako Pure Chemical, Osaka, Japan); RANKL is an indispensable component for osteoclast differentiation of RAW264.7 cells 22, 23) . The condition of the cells was observed daily by light microscopy. Cells cultured under the two different conditions (with or without RANKL) were fixed and stained using a TRAP staining kit (Cell Garage, Tokyo, Japan) according to the manufacturer's protocol on days 3 and 5 of culture.
Conditioned medium
RAW264.7 cells were cultured with or without 50 ng/ml RANKL for 3 days. The cell culture medium was then changed to -MEM without RANKL and FBS. Cells were cultured for an additional 24 h, and each culture medium sample collected was diluted to 30 %.
CD4
+ T cell isolation C57BL/6J mice were purchased from Sankyo Labo 
IL-18-induced GM-CSF expression in CD4 + T cells CD4
+ T cells were seeded at 1 × 10 5 cells/cm 2 in 96-well flatbottomed culture plates before collecting the supernatants. Cells were stimulated with 0 (control), 1 and 10 ng/ml IL-18 (Medical & Biological Laboratories, Nagoya, Japan) in the presence of the conditioned medium, which was collected from RANKL-treated or untreated RAW264.7 cells. The cells were cultured at 37 °C in a humidified incubator in a 5 % CO 2 atmosphere for 24 h.
Real-time reverse transcription (RT)-polymerase chain reaction (PCR)
Total RNA was isolated from cultured cells on days 3 and 5 using NucleoSpin RNA (Takara Bio, Shiga, Japan). The isolated RNA was then treated with DNase. The amount of DNase-treated RNA was measured using a NanoDrop 1000 (ND-1000; Thermo Fisher Scientific, Wilmington, DE, USA), and was converted into complementary DNA (cDNA) using an RNA PCR Kit (Takara Bio). The cDNA (0.2 g/2 l) was subjected to real-time PCR using SYBR Green I dye. The reactions were performed in 25 l of an SYBR premixed Ex Taq solution (Takara Bio) containing 20 M sense and anti-sense primers (Table 1) . PCR assays were performed using a Smart Cycler system (Cepheid, Sunnyvale, CA, USA) and analyzed using Smart Cycler software. The PCR protocol for IL-18 BP and IL-18 consisted of 30 cycles at 95 °C for 3 s and 60 °C for 20 s. All real-time PCR experiments were performed in triplicate, and the specificity of the PCR products was verified by melting curve analysis. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis
The culture medium from RAW264.7 cells was collected and dialyzed using a PD-10 column (GE Healthcare Bio-Science, Piscataway, NJ, USA). Next, the dialyzed culture medium was subjected to 10 % SDS-PAGE (gel size: 8.3 cm × 6.5 cm × 0.75 mm) with a discontinuous Tris-glycine buffer system 24) . Samples containing 20 g of extracellular proteins were dissolved in 10 l sample buffer containing 1 % SDS, 2 M urea, 15 mg/ml dithiothreitol, and bromophenol blue, and then heated at 95 °C for 5 min prior to loading. Proteins were resolved by SDS-PAGE, transferred to a polyvinylidene fluoride membrane using a semidry transfer apparatus, and probed with the indicated antibodies: polyclonal goat IgG antibodies against mouse IL-18BP (Acris Antibodies, San Diego, CA USA), followed by the appropriate biotin-conjugated secondary rabbit anti-goat IgG (Chemicon International, Temecula, CA, USA). Membranes were then labeled with streptavidin-horseradish peroxidase (HRP) and visualized using a commercial chemiluminescence kit (GE Healthcare BioScience).
Enzyme-linked immunosorbent assay (ELISA)
The amount of GM-CSF in the culture medium derived from CD4 + T cells was determined using a commercially available ELISA kit (BioLegend) according to the manufacturer's instructions. Assays were performed in triplicate, and the data were converted to pg GM-CSF/ ml.
Statistical analysis
All experiments were performed in triplicate. Each value represents the mean ± standard deviation (SD) of triplicate experiments. Significant differences (p < 0.05) were determined using Student's t-test or one-way analysis of variance (ANOVA) followed by the Bonferroni modification of Student's t-test.
Results
Effect of RANKL on TRAP staining and expression of IL-18BP and IL-18 in RAW264.7 cells
We first investigated the appearance of TRAP-positive multinucleated cells in the absence and presence of RANKL. We confirmed TRAP-positive multinucleated cells on days 3 and 5 of culture in the presence of RANKL, and their size on day 5 was larger than that on day 3 ( Fig. 1a and b) . We did not confirm TRAP-positive multinucleated cells on days 3 and 5 of culture in the absence of RANKL (Fig. 1c and d) .
We next sought to examine the effect of RANKL on mRNA expression of IL-18BP and IL-18. IL-18BP mRNA expression was significantly increased in cells cultured with RANKL compared with those without RANKL on days 3 and 5 of culture (Fig. 2) . However, IL-18 mRNA expression was significantly suppressed on days 3 and 5 by the addition of RANKL (Fig. 3) .
Effect of conditioned medium derived from RAW264.7 cells on IL-18-induced GM-CSF expression in CD4 + T cells.
Before examining conditioned medium, we confirmed whether the stimulatory effects of RANKL on IL-18BP expression were observed at the extracellular protein level. Protein levels of IL-18BP in the culture supernatants derived from RANKL-treated RAW264.7 cells were markedly higher than those in the culture supernatants derived from untreated RAW264.7 cells (Fig. 4) .
We next measured GM-CSF protein expression in the culture supernatants after stimulating CD4 + T cells with IL-18 in the presence of conditioned medium derived from RAW264.7 cells (Fig. 5) . GM-CSF expression was significantly higher in IL-18-stimulated CD4 + T cells (1 or 10 ng/ml) than in unstimulated control cells when CD4 + T cells were cultured with conditioned medium derived from unstimulated RAW264.7 cells. On the other hand, there was no significant difference in GM-CSF expression between IL-18-stimulated and unstimulated control CD4 + T cells when CD4 + T cells were cultured with conditioned medium derived from RANKL-stimulated RAW264.7 cells. Previous studies have reported that IL-18BP is secreted from human monocytes 19) , endothelial cells and macrophages 20) , or mouse cardiomyocytes 25) into culture supernatants. In the present study, we confirmed IL-18BP in the culture supernatants, and the expression levels of IL-18BP were markedly higher in the supernatants derived from RANKL-treated RAW264.7 cells than in untreated control cells. Foster et al. 19) reported that lipopolysaccharide (LPS) of Porphyromonas gingivalis, a Gramnegative bacterial species involved in alveolar bone resorption in chronic adult periodontitis 26, 27) , induced both IL-18 and IL-18BP secretion in THP-1 human monocytes. They also reported that when THP-1 cells were cultured with LPS and an anti-IL-18BP antibody, the antibody increased the concentration of unbound IL-18 in the supernatants; thus, IL-18BP in the culture supernatant can directly bind to IL-18, and the anti-IL-18BP antibody disrupted the binding of IL-18 and IL-18BP. In the present study, IL-18BP mRNA expression was increased, whereas IL-18 mRNA expression was decreased, when RAW264.7 cells were treated with RANKL. Therefore, we speculate that the culture supernatants derived from RANKL-treated RAW264.7 cells contain sufficient IL-18BP that can neutralize IL-18. Based on previous studies that reported the stimulatory effect of IL-18 on GM-CSF expression in CD4 + T cells [11] [12] [13] , we hypothesized that the free IL-18BP in culture supernatants derived from RANKL-treated RAW264. An increase in the level of IL-18 has been observed in the serum or pathological tissue in individuals with rheumatoid arthritis [28] [29] [30] [31] or periodontitis 32, 33) , both of which are well-recognized as inflammatory diseases with bone destruction, through RANKLinduced osteoclast formation [34] [35] [36] . The results in our present study may help explain how RANKL, IL-18 and IL-18BP are involved in the cell-cell interactions between osteoclast precursor cells and CD4 + T cells in these bone-destructive disorders. In the inflammatory environment where RANKL is dominant, IL-18 cannot induce the production of GM-CSF in CD4 + T cells, because RANKL stimulates IL-18BP production in the early stage of osteoclast differentiation from osteoclast precursor cells. Consequently, IL-18 may not interfere with RANKL-induced osteoclastogenesis in bone-destructive disorders.
In conclusion, the results of the present study suggest that RANKL suppresses the stimulatory effect of IL-18 on GM-CSF expression in CD4 + T cells via enhancing the production of IL-18BP in RAW264.7 cells.
